WO2016006838A1

WO2016006838A1 - Composition for preventing or alleviating periodontal disease, having increased anti-inflammatory and sterilizing strength

Info

Publication number: WO2016006838A1
Application number: PCT/KR2015/006198
Authority: WO
Inventors: 김순회; 손미원; 전준호; 박형근; 강민경
Original assignee: 동아제약 주식회사
Priority date: 2014-07-10
Filing date: 2015-06-18
Publication date: 2016-01-14
Also published as: KR20160007049A; CN113244250A; KR101636430B1; CN106456656A

Abstract

The present invention provides an oral composition for preventing and alleviating periodontal disease, containing glycyrrhizinic acid or salts thereof, panthenol, and tocopheryl acetate. The oral composition of the present invention induces excellent effects of dental plaque formation inhibition and gingivitis prevention on the basis of anti-inflammatory and sterilizing effects, and thus can be used for a use of preventing and alleviating periodontal disease.

Description

【Specification】

[Name of invention]

Composition for preventing or improving periodontal disease with enhanced anti-inflammatory and bactericidal properties

The present invention relates to an oral composition for improving and preventing periodontal disease, which is excellent in anti-inflammatory effect and at the same time increases the tooth adhesion of the fungicide by maximizing the bactericidal effect.

Background Art

. Periodontal disease is often referred to as flavour, and depending on the extent it is divided into gingivitis (gingivitis) and periodontitis (per iodontsis). A direct cause of periodontal disease is a bacterial film called plaque that is continuously formed on the teeth by bacteria in the oral cavity. If plaque is hardened without being removed, it becomes tartar. When plaque and tartar accumulate, the gum falls from the tooth, and as a result, a gap is formed and a periodontal sac is formed between the tooth and the gum, and the more severe periodontitis, the deeper the periodontal sac. As the periodontal sac becomes deeper, the periodontal ligament becomes inflamed and bone loss occurs. It is a relatively light and fast-recovering form of periodontal disease that is limited to gingiva (gum), or soft tissues, called gingivitis, and this inflammation progresses to the gingiva and alveolar bone (gum bone).

The cause of periodontitis is lipopolysaccharide (Lipopolysacchar ide, LPS), an inflammation-causing substance released by harmful bacteria present in the oral cavity. Inflammation is generated by swelling gums and bleeding caused by lipopolysaccharide, and many studies have been conducted to confirm the effect by adding anti-inflammatory substances (mainly herbal extracts) to improve such inflammation. In addition, there are examples of products that use panthenol and succitocope in domestic products and dipotassium glycyrrhinate in overseas products, but none of them are specifically selected and combined for the purpose of improving and preventing periodontal disease. It became.

Another cause of periodontitis is plaque and tartar. In order to prevent and improve plaque and tartar, sterilization of harmful bacteria in the oral cavity, which is a direct cause, is required. For this purpose, various fungicides are used in previous studies and commercial products. However, increasing the content of this enhances the effect, but oral irritation cannot be avoided, and the cost can not be ignored, so the content cannot be continuously increased.

Therefore, many studies have been carried out to increase the tooth adhesion rate of the same content of sterilizing substances by using incremental substances. In this regard, for example, Patent No. 10-2006-0089890 discloses a method of increasing the residual effect of triclosan in the oral cavity, and Patent No. 10-0659139 discloses a specific nonionic surfactant at an optimal compounding concentration. In order to enhance the composition, Patent No. 10-2012-0058713 discloses a composition containing polygamma glutamic acid to increase the retention of bivalent antimicrobial agents in the oral cavity. However, in accordance with these prior arts, only the prevention through the sterilization of periodontal causative bacteria using antibacterial action is possible, and the improvement effect on the existing gum inflammation is hardly expected. On the other hand, Patent No. 10-0167019 discloses to increase the tooth surface adsorption capacity of the bactericidal cetylpyridinium chloride by using the Ν ^α -long chain acyl basic amino acid lower alkyl esters or salts thereof, the effect as expected in actual application Not shown.

Therefore, the present inventors have studied intensively to develop a composition for oral cavity used for improving and preventing periodontal disease with less oral irritation and enhanced efficacy of periodontal disease. As a result, the anti-inflammatory effect is excellent and the tooth adhesion of the fungicide is increased. After securing an excellent composition that maximizes the bactericidal effect, it was confirmed that such a composition shows an excellent effect in clinical trials and completed the present invention.

[Detailed Description of the Invention]

[Technical problem]

One object of the present invention is to provide a pharmaceutical composition for preventing or treating periodontal disease at the same time excellent in anti-inflammatory and bactericidal effect.

Another object of the present invention is to provide an oral composition for preventing or improving periodontal disease at the same time excellent anti-inflammatory and bactericidal effect.

Technical Solution As one aspect for achieving the above object, the present invention provides a pharmaceutical composition for preventing or treating periodontal disease, including glycyrrhizin acid or a salt thereof, panthenol and tocope acetate.

As another aspect, the present invention provides an oral composition for preventing or improving periodontal disease, including glycyrrhizinic acid or a salt thereof, panthenol and tocope acetate. The compositions may further comprise a cationic fungicide.

The present invention provides a pharmaceutical composition for preventing or treating periodontal disease, comprising glycyrrhizin acid or a salt thereof, panthenol and tocopherol acetate.

The present invention also provides an oral composition for preventing or improving periodontal disease, including glycyrrhizin acid or a salt thereof, panthenol and tocopherol acetate.

【Effects of the Invention】

The composition of the present invention shows an excellent anti-gingival production and gingivitis prevention effect on the basis of anti-inflammatory and bactericidal effect, can be usefully used for preventing, improving or treating periodontal disease.

[Brief Description of Drawings]

Figure 1 is a graph of the anti-inflammatory test results represent the degree of NO production of Examples 1-9, Comparative Example 1-5.

2 and 3 show the change in the gingival index and the amount of change after 6 weeks when using Example 3-1 and general toothpaste in patients with gingivitis or mild periodontal disease.

4 and 5 show the change in the gingival index and the amount of change after 6 weeks when using Example 3-1 and general toothpaste in patients with gingivitis or mild periodontal disease.

[Best form for implementation of the invention]

The inventors of the present invention while studying to develop oral compositions for preventing and improving periodontal disease, which have excellent anti-inflammatory effect and bactericidal power, glycyrrhizin acid or It has been found that a combination of salts, panthenol and tocopherate acetate produces an excellent anti-inflammatory effect, and when it is used in a certain ratio, it is confirmed that the cationic fungicide increases the tooth adhesion and the sterilization power is also increased. The invention was completed.

Thus, in a preferred embodiment, the composition according to the invention may be a composition for anti-inflammatory, bactericidal or anti-plaque.

The glycyrrhizin acid used in the present invention is an ingredient derived from licorice and has an effect of inhibiting inflammation by reducing the production of an inflammatory reaction medium during the inflammatory reaction process, and in the present invention, a salt form such as dipotassium glycyric acid and ammonium glycyrrhinate It may also be used, but is not limited to the salts exemplified above.

It is important to adjust the composition content of glycyrrhizinic acid or its salts, as they can affect the tooth adhesion effects of cationic fungicides. As a specific aspect, the composition according to the present invention may be included in the glycyrilic acid or salt thereof in an amount of 0.001 to 2 parts by weight, 0.01 to 1 parts by weight or 0.05 to 0.5 parts by weight relative to 100 parts by weight of the total composition. If it contains more than 2 parts by weight, the flavor of the product is lowered and the surface adhesion of the cationic fungicide included together is reduced, affecting the sterilization power may reduce the effect.

Panthenol used in the present invention has the effect of promoting the growth of cells and recovery of tissues and preventing inflammation and redness to protect the oral wounds. When used in combination with tocopherol acetate and glycyrrhizinic acid or its salt dipotassium, it may have a better effect on improving gum inflammation. In one embodiment of the present invention, the panthenol may be included in 0.005 to 5 parts by weight, 0.01 to 3 parts by weight or 0.01 to 2 parts by weight relative to 100 parts by weight of the total composition. Less than 0.005 parts by weight of the effect on the improvement of periodontal disease and wound protection may be insignificant, in the case of more than 5 parts by weight of the increase in effect compared to the added amount may be inefficient.

Tocopherol acetate used in the present invention is a vitamin E, a substance that promotes blood circulation of gums and affects gum wound and inflammation healing, and is also widely known as an antioxidant substance. In one embodiment of the present invention, the tocopherate acetate is 0.01 to 1 parts by weight, 0.05 to 0.5 parts by weight or 0.1 to 0.5 to 100 parts by weight of the total composition Parts by weight may be included. Less than 0.05 parts by weight may have a minor effect and greater than 1 part by weight may affect the stability of the formulation.

In one embodiment of the invention, the composition may further comprise a cationic fungicide. The cationic fungicide, which has a cation and binds to the bacterial membrane or saliva protein, inhibits calculus and exhibits bactericidal action against bacteria in saliva. Specifically, cetylpyridinium chloride, nucleosalconium chloride, benzalkonium chloride and chlor nucleus. One or more selected from the group consisting of cydines may be used, and preferably cetylpyridinium chloride may be used, but is not limited thereto. In another embodiment of the present invention, the cationic fungicide may be included 0.01 to 1 parts by weight or 0.01 to 0.1 parts by weight relative to 100 parts by weight of the total composition, but is not limited thereto.

The composition for oral cavity may further include an additive, and may include, for example, additives such as fluorinated compounds, abrasives, wetting agents, sweeteners, flavoring agents, foaming agents, binders, preservatives, pH adjusting agents, and the like. It is not limited.

The fluorine compound is to act to prevent tooth decay by increasing the acid resistance of the teeth, for example, may be a single or a combination thereof selected from the group consisting of sodium fluoride, sodium monofluorophosphate, tin fluoride, preferably May be, but is not limited to, sodium monofluorophosphate. The fluorine compound may be included in an amount of 0.01 to 2 parts by weight, 0.1 to 1.5 parts by weight or 0.5 to 1 parts by weight based on 100 parts by weight of the total composition for oral cavity.

The abrasive may be a single or a combination thereof in the group consisting of silicon dioxide, calcium carbonate, hydrous alumina, calcium dihydrogen phosphate, and sodium bicarbonate, and may be included in an amount of 10 to 60 parts by weight based on 100 parts by weight of the total oral composition.

The humectant may be a single or a combination thereof selected from the group consisting of amorphous sorbide liquid, glycerin, propylene glycol and polyethylene glycol, and may be included in an amount of 3 to 60 parts by weight based on 100 parts by weight of the total oral composition. . The sweetening agent may be a single or a combination thereof selected from the group consisting of sodium saccharin, xyl, erythri, stevia, sucralose, acesulfame potassium and aspartame, based on 100 parts by weight of the total oral composition 0.01 to 2 It may be included in parts by weight.

The flavoring agent may be a single or a combination thereof selected from the group consisting of peppermint oil, spearmint oil, and menthol, and the content of the flavoring agent may be a content commonly used in oral compositions, and is not particularly limited. Do not.

The foaming agent is a single or a combination thereof selected from the group consisting of sodium lauryl sulfate, sodium lauryl sarcosinate, cocamydopropyl, polyoxyethylene hydrogenated castor oil and polyoxyethylene polyoxypropylene based condensation polymer It may be water and may be included in an amount of 0.5 to 5 parts by weight based on 100 parts by weight of the total composition for oral cavity.

The binder may be a single or a combination thereof selected from the group consisting of carrageenan, xanthan gum, carboxymethyl cellulose sodium, and polyvinylpyrrolidone, and may be present in an amount of from 0.01 to 100 parts by weight of the total oral composition. It may be included in 5 parts by weight.

The preservative may be methylparaben or propylparaben.

The pH adjusting agent may be a single or a combination thereof selected from the group consisting of sodium dihydrogen phosphate, sodium dihydrogen phosphate, citric acid, sodium citrate, phosphoric acid, tartaric acid, sodium tartarate, the composition for oral cavity according to the present invention is the pH adjusting agent Can be adjusted to an appropriate pH, for example pH 5-8.

The composition according to the present invention may be prepared in various formulations, and in particular, may have formulations such as toothpaste, mouthwash, mouthwash, oral massage cream, and the like. In addition, the compounding composition of the composition for oral cavity provided in the present invention can be used in various combinations according to the use and type of the composition in addition to the components described above.

[Form for implementation of invention]

Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the present invention. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Preparation Example 1 Compositions of Examples 1 to 9 and Comparative Examples 1 to 5

Compositions of various concentrations of gum inflammation improving components were prepared as shown in Table 1 below, and compositions were prepared only with the compositions shown in the following table to exclude the influence of other raw materials added to the formulation.

The components of the composition used as the comparative example are shown in Tables 2 to 3.

Comparative Example 4 was prepared to have the same composition as the commercially available products for the comparison of the composition of the active ingredient of the Prodontax (GSK) and dentifrice (Donghwa Chemical Co.) and the present invention for periodontal disease. Example 5 was prepared to confirm the effect of the solvent on the composition.

Table 11

Table 2

[Table 3] Content (%) Chamomile tin Latania Tinak Myrrh Tin ethane Purified water Comparative Example 4 0. 125 0. 125 0.062 5 to 100 Comparative Example 5-ᅳ ᅳ 5 to 100

Preparation Example 2 Preparation of Liquid Toothpaste of Examples 1-1 to 9-1 and Comparative Examples 1-1 to 1-3

Liquid toothpaste was prepared to confirm the bactericidal power of the liquid toothpaste, a cationic fungicide base made by adding the inflammation improving composition.

As toothpastes of Examples 1-1 to 9-1 and Comparative Examples 1-1 to 1-3, sodium glycofluoride phosphate 0.76 using dipotassium glycyrrhizin acid, panthenol, and tocopeacetate as shown in Table 4 below. Weight ¾>, cetylpyridinium chloride 0.05% by weight, polyoxyl hydrogenated castor oil 0.5% by weight, ethanol 5% by weight, used as a flavoring agent, liquid toothpaste is prepared by adding purified water to a total content of 100% by weight It was. Tocopherate acetate, flavoring agent, and polyoxyl hydrogenated castor oil are dissolved in ethane, and the remaining components are dissolved in purified water. First, a solution of the prepared ethanol bath was put in a purified water bath to dissolve, and then prepared by just applying.

Table 4

Content (%) Di Potassium Diglyceride Panthenol Acetate Tocope Example 1-1 0.005 1 0.2 Example 2-1 0.01 1 0.2 Example 3-1 0.1 1 0.2 Example 4-1 1 1 0.2 Example 5-1 0 0.01 0.01 Example 6-1 0.1 0.1 0.2 Example 7-1 0.1 3 0.2 Example 8-1 0.1 0.1 0.05

Example 9-1 0.1 1 0.5

Comparative Example 1-1 0.1 0 _, 0

Comparative Example 2-1 0 1 0

Comparative Example 3-1 0 0 0.2 Test Example 1 Evaluation of Nitric Oxide (NO) Formation Inhibitory Activity

In order to confirm the anti-inflammatory effects of di-potassium glycyrrhizinate by concentration, L. derived from P. gingival is, a periodontal disease-causing bacterium, causes inflammation, and the amount of NO, an inflammatory mediator generated after LPS treatment, was evaluated. The extent of reduction by the material was evaluated. The specific method is as follows.

Raw 264.7 cells (KCLB, Korea) were seeded in 96 well plates and incubated for 24 hours. Change the medium (DMEM medium + 1 FBS + penicillin + streptomycin), drug treatment after about 1 hour, LPS treatment 1 hour after drug treatment to take 50uL of the medium cultured cells after 24 hours to measure the solution (1 The amount of NO produced was measured by absorbance at 540 nm by mixing with 1% sulfanilamide in 5% phosphoric acid and 0.1% napht hy 1 ethylenediamine in 5% phosphoric acid. . The results are shown in Table 5 below and FIG. 1.

Table 5

NO Production Amount (ug / mL)

1.65

Example 2 1.63

Example 3 1.58

Example 4 1.52

Example 5 1.68

Example 6 1.63

Example 7 1.62

Example 8 1.72

Example 9 1.65

Comparative Example 1 1.87

Comparative Example 2 1.95

Comparative Example 3 2.2

Comparative Example 4 2.13

Comparative Example 5 3

Control (LPS) 3.2 As shown in Table 5 and Figure 1, when compared with Comparative Examples 1 to 5 excellent effect of reducing the amount of NO produced as a mediator of inflammation in the composition of the example containing all of the potassium glycyrrhizin, panthenol, tocopherate acetate Appeared. In addition, Examples 1 to 9 showed better anti-inflammatory action than Comparative Example 4, which is a composition of a commercially available product.

In the examples, the NO production amount change was confirmed according to the concentration of the three substance composition, but the effect of panthenol and tocopherate acetate did not increase at a certain concentration or more.

Additional tests were performed to determine the effect of these anti-inflammatory substances on the formulation.

Test Example 2 Evaluation of Surface Adhesion of Cationic Fungicide

250 mg of hydroxyapatite (HA) (Bio-Rad Laboratories, Inc., U.S.) was molded into a diameter of 13 睡 and then sintered at 600 ^° C. for 6 hours to prepare HA di sc. It was placed in 2 mL of collected saliva and left for 18 hours to be pretreated. Then, the test solution of Examples 1-1 to 9-1 and Comparative Examples 1-1 to 3-1 was transferred to a vial containing 1 mL each, 37 ^It was added to the water bath of ^° COOrpm conditions and reacted for 30 minutes. Then remove the di sc, wash the test solution on the surface with 6 mL of distilled water, and put it in a vial containing lOmL of extraction solvent (50 mM sodium lauryl sulfate, 40 mM citrate complete solution (ρΗ3 · 0) / acetonitrile = 30/70) Soni cat ion for a minute. The extracted solution was filtered with a 0.45um filter and analyzed by HPLC according to the quantitative analysis of Cetylpyr idinium chloride (CPC). The results are shown in Table 6 below.

Table 6

Classification CPC (ug / mL)

Example 1-1 19.9

Example 2-1 19.8

Example 3-1 19.9

Example 4-1 15.8 Example 5-1 17.6

Example 6-1 18.6

Example 7-1 20. 1

Example 8-1 18.7

Example 9-1 18.8

Comparative Example 1-1 13.3

Comparative Example 2-1 20.9

Comparative Example 3-1 20.3 As a result of evaluating the adsorption power of the Example prepared by adding di Potassium glycyrrhinate and Panthenol, the potassium Potassium Glyciric acid decreased the adsorption power of the fungicide, whereas Panthenol increased the tooth adhesion of the cetylpyridinium chloride. It was.

First, G.U.M Dental Rinse GNN, a commercial product containing the same type and similar ingredients

The tooth adhesion of cetylpyridinium chloride of (Suns tar, Japan) was confirmed, and the value was 12.6 ug / mL. As shown in Table 7, the tooth surface contact strength of Examples 1-1 to 9-1 was better than that of GM Dentallins. In comparison with the results of the comparative example, it was confirmed that in the formulations of Examples 1-1 to 9-1 composition, the tooth adhesion was increased as the amount of diglyceride diglyceride and the amount of panthenol increased. The content appeared to be important. The content of dipotassium glycyrrhizin acid and panthenol in the above-mentioned examples showed that the surface adhesion of cetylpyridinium chloride was improved. Example 3-1 showed the best results when combining the two test-anti-inflammatory effects and tooth adhesion of cetylpyridinium chloride.

In addition, bactericidal effect was expected to be enhanced by improving the adhesion of the toothpaste. Example 2-1 showed the best result and the comparative example 1-1 showed the low adsorption of the tooth surface. Proceeded. <Test Example 3> bactericidal power test for periodontal pathogens

Adhesion and suspension antimicrobial activity of two strains known as periodontal disease, Porphyro nas gingival is ^ Aggregatibacter actinc ycetemcomitans ⁶ ^ Proceeded. It was confirmed that the sterilization ability was improved by improving the adhesive force by comparing the formulation with high adsorption power of the sterilizing material and the low formulation.

[Porphyromonas gingival is cultured]

Bacteria were inoculated into TSA medium containing sheep blood and hem in menadione and placed in an anaerobic container until cultured colonies were observed in a 37 ^° C incubator. When colonies were observed, 5% Horse serum and Hemine menadione Inoculated with the added TSB and incubated to A ₅₆₀ = 0.7 (about lxi0 ^{9 '} cells /). After subculture, inoculated TSB medium and cultured 0.1% of horse serum and hem in menadione in 75cuf cell culture flasks and incubated for 8 days with medium replacement every 24 hours.

[Aggregatibacter act inomycetemcomi tans culture]

BHI agar was inoculated with bacteria and incubated at 37 ^° C and 5% C0 ₂ incubator until bacterial colonies were observed. When colonies were observed, they were inoculated into BHI broth and cultured to A ₅₆₀ = 0.7 (about 1 10 ⁹ cells /). BHI broth and culture were inoculated into 75cui ² Cell culture flasks and cultured for 3 days with medium replacement every 24 hours.

[Adhesion Test (Biofilm Method)]

After incubating the bacteria. Discard the culture in the flask. After washing the inside of the flask three times with PBS, 3 test solutions were added and shaken for 18 seconds. After washing the inside of the flask three times with PBS, 1 m of PBS was added and the biofilm was scraped off with a cell scraper. The scraped biofilm was vortexed for 15 seconds. Stain the suspension onto BHI Agar and TSA plates prepared by diluting the suspension 10 times with PBS. Colonies were observed after 3 days of ac t nomycet emcom i ans and 7 days of P. gingival is. Negative control group was treated with PBS instead of test solution. [Planktonic Method]

1 bacteria cultured in Broth were collected, centrifuged at 13,500 rpm, and the supernatant was removed. The test solution was added to the precipitate, ground for 15 seconds, and then centrifuged at 13,500 rpm for 30 seconds. After removing the supernatant, it was washed three times with PBS and suspended with 1 PBS. BHI and TSA prepared by diluting the suspension 10 times with PBS. Smear the plate and A. Colonies were observed after 3 days of ac ti nomyce t emcom ί t ans and 7 days of P. gingival is. Negative control group was treated with PBS instead of test solution.

[Equation 1]

Count viable count: N = CXD

N: viable count, C: colony count (average number of colonies), D: dilution factor (dilution factor of diluent)

[Equation 2]

Reduction rate:

D: viable cell count reduction rate, A: viable cell number in the control group, B: viable cell number adhesion test results in the sample treatment group are shown in Table 7, and the suspension test results are shown in Table 8. Table 7

**% i 11 compared to PBS control.

Table 8

* Mean (SD) Log ₁₀ _trans formed counts to test solution.

**% Kill compared to PBS control. As shown in Table 8 and Table 9 Example 3-1 of the composition of the higher the surface adhesion of the cationic disinfectant showed excellent bactericidal power against the cause bacteria of periodontal disease. In addition, the sterilization power was increased as the tooth adhesion increased. Therefore, with all these test results, the periodontal inflammation improvement and prevention effect of Example 3-1 was confirmed through the clinical trials as follows.

<Test Example 4> Measurement of plaque and gingival index

In order to confirm the plaque and gingival index of the present invention, a test was conducted by recruiting subjects from a dental hospital. Forty-six adult men and women with gingivitis and mild periodontitis were tested with open-label liquid toothpaste (Gagrin © 333) and Example 3-1 of the present invention under an open label. The test period was 6 weeks. Baseline was measured and scaled before the test, and plaque index (PI) and gingival index (GI) were measured at 2, 4 and 6 weeks. Toothpaste was used three times a day after meals during the trial period. The plaque index was determined using the Loe-Silness plaque index (PI) in the upper and lower representative teeth, # 16, 21, 24, 36, 41, 44, and the plaque colorant (GUM Red cote, Suns tar Butler, Chicago, IL, USA). The total PI scores per subject were determined by the average of each tooth score by scoring at 6 sites per tooth (pure cotton, distal cotton, mesial cotton, snow surface, distal surface, mesial surface).

The gingival index is the Loe-Silness gingival index (GI) in teeth # 16, 21, 24, 36, 41, 44. ), And the total GI scores per subject were calculated as the average of each tooth score.

The test results are shown in Table 9 below and FIGS. 2 to 5.

Table 9

Mean SD Mean SD Mean SD Mean SD

0 1.82 0.22 1.71 0.32 1.36 0.23 1.34 0.34

2 0.87 0.41 0.59 0.48 ^* 0.88 0.7 0.54 0.59

4 0.93 0.45 0.34 0.25 ^* 0.89 0.48 0.33 0.42 ^*

6 0.88 0.47 0.39 0.30 ^* 1.01 0.58 0.36 0.43 ^*

(* p <0.05) According to Table 9 and FIGS. 2 and 4, the plaque index (PI) and the gingival index (Gi) decreased with time in both groups, but after 6 weeks, the results of Example 3-1 PI, GI index was further reduced, showing a great improvement rate compared to general toothpaste, showing excellent plaque production (Example 77.19% vs. control 51.65%) and inhibition of gingivitis (Example 73.13% vs. control 25.74%) (FIG. 3 and 5). In addition, no adverse reactions and adverse events were reported during the trial.

As described above, the oral composition for preventing and improving periodontal disease containing cetylpyridinium chloride, sodium monofluorophosphate tocopherol acetate, glycosyl dipotassium and panthenol showed excellent effects in the gingival index and plaque index. Therefore, it can be seen that through the combination of the five components of the anti-inflammatory action, the addition of panthenol improves the adhesion of the tooth surface, and through the strengthening of antimicrobial action through the improvement of periodontal disease is further increased.

Claims

[Claim]

[Claim 1]

Glycyrrhizinic acid or salts thereof. Oral composition for preventing or improving periodontal disease, including panthenol and tocopherol acetate.

[Claim 2]

According to claim U, further comprising a cationic fungicide, periodontal disease prevention or improvement composition.

[Claim 3]

The oral composition of claim 2, wherein the cationic fungicide is at least one selected from the group consisting of cetylpyridinium chloride, nucleosalconium chloride, benzalkonium chloride, and chlornucleosides.

[Claim 4]

The oral composition of claim 1 or 2, wherein the glycyrrhizinic acid or salt thereof is included in an amount of 0.001 to 2 parts by weight based on 100 parts by weight of the total composition.

[Claim 5]

According to claim 1 or 2, wherein the panthenol is 0.005 to 5 parts by weight based on 100 parts by weight of the total composition, periodontal disease prevention or improvement oral composition.

【Claim 6】.

According to claim 1 or Crab, wherein the tocopherate is contained from 0.01 to 1 parts by weight relative to 100 parts by weight of the total composition, oral composition for preventing or improving periodontal disease.

[Claim 7]

According to claim 2, wherein the cationic fungicide is 0.01 to 5 parts by weight relative to 100 parts by weight of the total composition, periodontal disease prevention or improvement oral composition.

[Claim 8]

The oral composition for preventing or improving periodontal disease according to claim U or 2, further comprising a fluorine compound.

[Claim 9] The oral composition of claim 8, wherein the fluorine compound is included in an amount of 0.01 to 2 parts by weight based on 100 parts by weight of the total composition.

[Claim 10]

The oral composition of claim 1, wherein the formulation of the oral composition is toothpaste, mouthwash, mouthwash or gum massage cream.

[Claim 111]

The oral composition according to claim U, wherein the pharmaceutical composition has anti-inflammatory, bactericidal or anti-plaque activity.

[Claim 12]

A pharmaceutical composition for preventing or treating periodontal disease, comprising glycyrrhizinic acid or a salt thereof, panthenol and tocope acetate.

[Claim 13]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12, further comprising a cationic fungicide.

[Claim 14]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 13, wherein the cationic fungicide is at least one selected from the group consisting of cetylpyridinium chloride, nucleosalconium chloride, benzalkonium chloride, and chlornucleoside. .

[Claim 15]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12 or 13, wherein the glycyrrhizinic acid or salt thereof is included in an amount of 0.001 to 2 parts by weight based on 100 parts by weight of the total composition.

[Claim 16]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12 or 13, wherein the panthenol is contained in an amount of 0.005 to 5 parts by weight based on 100 parts by weight of the total composition.

[Claim 17]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12 or 13, wherein the tocopherate is contained in an amount of 0.01 to 1 part by weight based on 100 parts by weight of the total composition.

[Claim 18]

According to claim 13, wherein the cationic fungicide is 0.01 to 5 parts by weight relative to 100 parts by weight of the total composition, periodontal disease prevention or treatment pharmaceutical composition.

[Claim 19]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12 or 13, further comprising a fluorine compound.

[Claim 20]

. The pharmaceutical composition for preventing or treating periodontal disease according to claim 19, wherein the fluorine compound is included in an amount of 0.01 to 2 parts by weight based on 100 parts by weight of the total composition.

[Claim 21]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12, wherein the dosage form of the pharmaceutical composition is a toothpaste, a mouthwash, a mouthwash tablet, or a gum massage cream. [Claim 22]

The pharmaceutical composition for preventing or treating periodontal disease according to claim 12, wherein the pharmaceutical composition has anti-inflammatory, bactericidal or anti-plaque activity.